Efficient CD44-targeted magnetic resonance imaging (MRI) of breast cancer cells using hyaluronic acid (HA)-modified MnFe2O4 nanocrystals by 서진석 et al.
Lee et al. Nanoscale Research Letters 2013, 8:149
http://www.nanoscalereslett.com/content/8/1/149NANO EXPRESS Open AccessEfficient CD44-targeted magnetic resonance
imaging (MRI) of breast cancer cells using
hyaluronic acid (HA)-modified MnFe2O4
nanocrystals
Taeksu Lee1, Eun-Kyung Lim2,3, Jaemin Lee1, Byunghoon Kang1, Jihye Choi1, Hyo Seon Park5, Jin-Suck Suh2,3,4,
Yong-Min Huh2,3,4* and Seungjoo Haam1,3*Abstract
Targeted molecular imaging with hyaluronic acid (HA) has been highlighted in the diagnosis and treatment of
CD44-overexpressing cancer. CD44, a receptor for HA, is closely related to the growth of cancer including
proliferation, metastasis, invasion, and angiogenesis. For the efficient detection of CD44, we fabricated a few kinds
of HA-modified MnFe2O4 nanocrystals (MNCs) to serve as specific magnetic resonance (MR) contrast agents
(HA-MRCAs) and compared physicochemical properties, biocompatibility, and the CD44 targeting efficiency.
Hydrophobic MNCs were efficiently phase-transferred using aminated polysorbate 80 (P80) synthesized by
introducing spermine molecules on the hydroxyl groups of P80. Subsequently, a few kinds of HA-MRCAs were
fabricated, conjugating different ratios of HA on the equal amount of phase-transferred MNCs. The optimized
conjugation ratio of HA against magnetic content was identified to exhibit not only effective CD44 finding ability
but also high cell viability through in vitro experiments. The results of this study demonstrate that the suggested
HA-MRCA shows strong potential to be used for accurate tumor diagnosis.
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CD44 is a cell-surface glycoprotein antigen of breast
cancer cells that is well known for its specific binding
with hyaluronic acid (HA) [1-3]. It is the multifunctional
cell-surface molecule involved in pathologic properties
of cancer cells such as cell proliferation, differentiation,
migration, angiogenesis, and chemokines [4-6]. There-
fore, detecting CD44 is vital for accurate diagnosis as
well as identifying effective anticancer drugs. Especially,
when HA binds with CD44, this binding-mediated sig-
nals trigger cytological activities such as structural
changes in the membrane and tumor cell migration
[7-10]. Hence, HA has been frequently utilized as a* Correspondence: ymhuh@yuhs.ac; haam@yonsei.ac.kr
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in any medium, provided the original work is ptargeting moiety to detect CD44 in the diagnosis and
treatment of specific cancers directly associated with
CD44 [11-14].
For sensitive and specific detection of cancer via the
CD44 receptor, molecular imaging has been strongly
considered due to the accurate acquisition of highly sen-
sitive images and deeper insight into in vivo conditions
[15-17]. Of the various molecular imaging techniques,
magnetic resonance (MR) imaging has been widely
recommended because it is non-invasive and provides
high-resolution and tomographic real-time images at the
cellular and molecular levels [18-20]. Therefore, CD44-
targeted MR imaging has been applied in the treatment
of cancer such as monitoring therapeutic efficacy and
determining the progonosis of cancer.
To facilitate better interpretation of the MR images,
recently developed MnFe2O4 nanocrystals (MNCs), syn-
thesized by the thermal decomposition method in the
organic phase, are well suited because of their finepen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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an excellent size and composition control [21,22]. How-
ever, these MNCs are insoluble in aqueous phase and
could not be used directly in biomedical applications, so
appropriate modification is necessary for phase transfer
as well as further conjugation of specific targeting moi-
eties such as HA [23,24]. In addition, identification of
specific amounts of targeting moieties on the MNCs
resulted in the most efficient cellular uptake and imaging
in vitro [25]. Therefore, finding the optimal HA density
on MNCs is needed for the most effective diagnosis and
treatment for CD44-overexpressed breast cancer.
Herein, we report the development of HA-modified
MR contrast agents (HA-MRCAs) for utilization in the
efficient targeted detection and diagnosis of CD44-
overexpressing cancer via MR imaging. Water-soluble
aminated MNCs (A-MNCs) were firstly formulated via
the nano-emulsion method. To investigate the optimal
amount of HA for CD44 targeting with high efficiency,
HA-MRCAs were prepared by conjugating different
amounts of HA molecules to the A-MNCs (Figure 1).
HA-MRCAs preserved colloidal stability and represented
CD44 targeting ability as well as enhanced cell viabilities
due to the modification with HA. The physicochemical
properties and biocompatibilities of HA-MRCAs were
fully characterized, and their enhanced sensitivity with se-
lective binding to the CD44-abundant cancer cells was
comparatively investigated via MR imaging.Figure 1 Schematic illustration of the synthesis of HA-conjugated MRMethods
Materials
Polysorbate 80 (polyoxyethylene sorbitan monooleate,
P80), spermine, 1,10-carbonyldiimidaziole (CDI), 1,4-
dioxane (99.8%), iron(III) acetylacetonate, manganese
(II) acetylacetonate, 1,2-hexadecanediol, dodecanoic
acid, dodecylamine, benzyl ether, and 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) were pur-
chased from Sigma-Aldrich Chemical (St. Louis, MO,
USA). Hyaluronic acid (20 kDa) was obtained from
Lifecore Biomedicals (Chaska, MN, USA). Phosphate-
buffered saline (PBS; 10 mM, pH 7.4), Dulbecco's modi-
fied Eagle's medium, Roswell Park Memorial Institute
medium (RPMI), and fetal bovine serum (FBS) were
purchased from Gibco (Life Technologies, Carlsbad,
CA, USA). Both MDA-MB-231 and MCF-7 cells, breast
carcinoma cell lines [26-28], were obtained from the
American Type Culture Collection (Manassas, VA,
USA). Sulfo-N-hydroxysuccinimide (sulfo-NHS) and
2,4,6-trinitrobenzene sulfonic acid (TNBSA) solution were
purchased from Pierce (Thermo Scientific, Waltham,
MA, USA). All other chemicals and reagents were of
analytical grade.
Synthesis of MNCs
Monodispered magnetic nanocrystals, soluble in hydro-
phobic solvent, were synthesized using the thermal de-
composition method [21]. First, iron(III) acetylacetonatecontrast agents.
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hexadecanediol (10 mmol), dodecanoic acid (6 mmol),
and dodecylamine (6 mmol) were dissolved in 20 mL of
benzyl ether under a blanket of nitrogen. The mixture was
reacted for 2 h at 200°C and then further heated at 300°C
for 1 h. All processes were under nitrogen atmosphere.
After the mixtures were cooled at room temperature, the
products were purified twice with 20 mL of pure ethanol.
Finally, MNCs were grown to approximately 12 nm by the
seed-mediated growth method.
Preparation of A-MNCs and HA-MRCAs
A-MNCs were fabricated using the nano-emulsion
method [23]. First, 10 mg of MNCs was dissolved in 4
mL of n-hexane (organic phase). The organic phase was
injected into 30 mL of de-ionized water (aqueous phase)
containing 100 mg of aminated P80. After mutual satur-
ation, the solution was emulsified for 20 min under
ultrasonification (ULH700S, Ulssohitech, Cheongwon-gun,
South Korea) at 450 W. The mixture was kept overnight
at room temperature to remove the volatile organic
solvent. The products were purified using a centrifugal
filter (Centriprep YM-3, 3-kDa molecular weight cutoff
(MWCO), Amicon, Millipore Corporation, Billerica,
MA, USA) in triplicate at 3,000 rpm for 30 min.
HA-MRCAs with different molar ratios of HA were fab-
ricated by EDC-NHS chemistry. First, the pH of the A-
MNC solution was adjusted to neutral condition by the
addition of 0.1 N HCl solution. Then, various amounts of
HA (0.43, 1.7, and 6.8 μmol) were dissolved in the 40 mL
of de-ionized water followed by the addition of EDC and
sulfo-NHS. Each HA solution was added to A-MNC solu-
tion containing 5 mg of MNCs. The HA and A-MNCs
were reacted for 2 h at room temperature. Finally, EDC,
sulfo-NHS, and unbound HA were removed using dialysis
(MWCO, 25, 000) against excess de-ionized water.
Characterization of A-MNCs and HA-MRCAs
The size distributions and zeta potential values of A-
MNCs and HA-MRCAs were measured using laser scat-
tering (ELS-Z, Otsuka Electronics, Osaka, Japan). The
inorganic ratios (%) and the crystallinities of magnetic
nanocrystals in A-MNCs and HA-MRCAs were analyzed
using a thermo-gravimetric analyzer (SDT-Q600, TA In-
struments, Newcastle, DE, USA) and X-ray diffraction
(X-ray diffractometer Ultima3, Rigaku, Tokyo, Japan) at
25°C, respectively. The magnetic properties of A-MNCs
and HA-MRCAs were also detected by a vibration sam-
ple magnetometer (model 9407, Lake Shore Cryotronics,
Inc., Westerville, OH, USA) at 25°C.
Cell viability assay for A-MNCs and HA-MRCAs
The cytotoxic effect of A-MNCs and HA-MRCAs against
MDA-MB-231 cells (CD44-abundant cancer cell line) wasanalyzed by measuring the inhibition of cell growth using
an assay for WST-1 ((4-(3-(4-lodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio)-1,3-benzene disulfonate)). MDA-MB-231
cells were maintained in RPMI containing 10% FBS and 1%
antibiotics at 37°C in a humidified atmosphere with 5%
CO2. MDA-MB-231 cells were harvested at a density of
1.0 × 104 cells/100 μL in a 96-well plate and incubated
at 37°C in 5% CO2 atmosphere overnight. The cells were
then treated with various concentrations of A-MNCs
and HA-MRCAs for 24 h. After incubation, the cells
were rinsed with 100 μL PBS (pH 7.4, 1 mM), and then
10 μL of WST-1 solution was added to each well. The
absorbance was measured at 450 nm with a reference
wavelength of 600 nm. The relative percentage of cell
viability was determined as the ratio of formazan inten-
sity in viable cells treated with A-MNCs and HA-
MRCAs to the intensity in non-treated (control) cells
[29-31].
Cellular targeting efficiency of HA-MRCAs
The targeting efficiency of HA-MRCAs was examined
by MR imaging of breast carcinoma cell line MDA-MB
-231 cells (high CD44 expression) and MCF-7 cells (low
CD44 expression). First, target cells (1.0 × 107 cells)
were harvested and washed three times with blocking
buffer (FBS (0.2%) and NaN3 (0.02%) in phosphate-
buffered solution (pH 7.4, 10 mM)) to inhibit
non-specific binding effects. The solutions containing
HA-MRCAs were applied to each cell line (1 and 0.5 μg,
respectively) at 4°C for 30 min. The cells were then
washed with blocking buffer three times to remove non-
binding HA-MRCAs. Next, 200 μL of 4% paraformalde-
hyde was added to re-suspend the cells. After targeting
efficiency was analyzed via MRI, the cells were dissolved
in nitric acid for 2 h at 180°C, and the concentrations of
magnetic nanocrystals (Fe + Mn) were measured using
inductively coupled plasma atomic emission spectrom-
etry (ICP-AES).
MR imaging procedures
We performed in vitro MR imaging experiments with a
1.5-T clinical MRI instrument with a micro-47 surface coil
(Intera, Philips Medical Systems, Best, The Netherlands).
The T2 weights of the A-MNC- and HA-MRCA-treated
cells (MDA-MB-231 and MCF-7 cells) were measured by
the Carr-Purcell-Meiboom-Gill (CPMG) sequence at room
temperature with the following parameters: TR = 10 s, 32
echoes with 12-ms even echo space, number of acquisi-
tions = 1, point resolution of 156 × 156 μm, and section
thickness of 0.6 mm. For acquisition of T2-weighted MR
images of A-MNC- and HA-MRCA-treated cells, the fol-
lowing parameters were adopted: resolution of 234 × 234
μm, section thickness of 2.0 mm, TE = 60 ms, TR = 4,000
ms, and number of acquisitions = 1.
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Characterization of aminated P80
MNCs, soluble in non-polar organic solvent with high
monodispersity, were made using the thermal decom-
position method to serve as MR contrast agents. For the
identification of optimal HA density for efficient CD44-
overexpressed breast cancer cell imaging and phase
transference of hydrophobic MNCs into aqueous phase,
the tri-hydroxyl groups of polysorbate 80 (P80) were
modified with amine groups using spermine and the
cross linker, 1,10-carbonyldiimidazole (CDI) [32]. CDI
was used to activate hydroxyl groups of P80 and gener-
ate reactive imidazole carbamate intermediates. When
the amine group of spermine attacked the intermediate,
imidazoles were released, and stable tri-urethane (N-alkyl
carbamate) linkages were fabricated. After conjugation,
the characteristic bands of aminated P80 were verified by
FT-IR spectra, which represented N-H stretching of an
amine group (3,550 cm−1), C-N stretching of an amide
group (3,400 cm−1), and N-H bending of an amine group
(1,600 cm−1) (Additional file 1: Figure S1). On the con-
trary, the O-H stretching of hydroxyl groups (3,500 cm−1)
of P80 was not detected in aminated P80 because all hy-
droxyl groups of P80 reacted with excess CDI. Further-
more, the chemical structures of aminated P80 were
analyzed by 1H-NMR to show δ values of 7.11 (−CONH-),
4.29 (−NH2), 3.22 (−OCH2-), 2.72, 1.77 (−CH2-), and 2.17
(−NH-) ppm (Additional file 1: Figure S2). To quantify
the primary amine groups (−NH2) in aminated P80, a
TNBSA assay was used since primary amine groups re-
place sulfonic acid groups in TNBS molecules. There-
fore, this substitution produces a chromogenic complex
for which the absorbance at 355 nm is proportional to
the number of amine groups (Additional file 1: Figure
S3) [33]. A standard curve was created using glycine be-
cause this amino acid molecule possesses one primary
amine group per molecule. The absorbance of aminated
P80 confirmed that the number of primary amine
groups in aminated P80 was approximately 2.4-fold
higher than that of glycine. These results showed that
all hydroxyl groups of P80 were modified with amine
groups, and the MNCs could be modified with HA
through the generation of an amide bond.
Synthesis and characterization of A-MNCs and HA-MRCAs
Subsequently, A-MNCs were fabricated with pre-
synthesized aminated P80 through the nano-emulsion
method. The HA, CD44-targeting polysaccharide, was
conjugated to the A-MNCs by EDC/NHS chemistry to
provide breast cancer cell affinity. Carboxylic acid
groups in HA were activated by EDC, and then sulfo-
NHS was reacted to generate sulfo-NHS ester. Amine
groups as nucleophiles on the A-MNCs were conjugated
with these activated ester groups, and the NHS grouprapidly left the intermediates, thereby creating stable
amide linkages between A-MNCs and HA to form HA-
MRCAs [34].
Various HA-MRCAs were prepared by changing the
amount of HA to equal that of A-MNCs (HA-MRCAs
(i) 4.4 × 10−1 μmol, HA-MRCAs (ii) 1.7 μmol, HA-
MRCAs (iii) 7.0 μmol and A-MNCs were fixed to MNCs
of 5 mg) for comparing the targeting efficiency with re-
spect to the amount of HA. Their average sizes were
measured using light scattering (A-MNCs, 54.9 ± 4.6
nm; HA-MRCAs (i), 140.5 ± 12.6 nm; HA-MRCAs (ii),
197.8 ± 26.3 nm; HA-MRCAs (iii), 233.8 ± 5.2 nm). As
expected, the size of HA-MRCAs proportionally increased
with increasing amount of conjugated HA (Figure 2a) due
to the increase in the organic layer, and this was also con-
firmed by thermogravity measurement (Figure 2b). Light
scattering represented that both A-MNCs and HA-
MRCAs were also well dispersed in the aqueous phase
without aggregation because of the steric hindrance by
hydrogen bonding with the biocompatible polymer HA
and aminated P80 on the coating layer of nanoparticles
and water. It was also confirmed by TEM images
(Additional file 1: Figure S4) [1,22]. The surface charge of
A-MNCs was strongly positive (36.3 ± 6.6 mV) due to the
abundant amine groups. HA-MRCAs (i) revealed a weak
positive charge (9.16 ± 0.9 mV) owing to the remaining
amine groups, whereas HA-MRCAs exhibited a negative
charge (HA-MRCAs (ii), −34.5 ± 1.0 mV; HA-MRCAs
(iii), −32.8 ± 0.5 mV) because aminated surfaces were cov-
ered with the carboxlic groups of HA (Figure 2a). We ex-
amined the colloidal stability of A-MNCs and HA-MRCAs
against various pH conditions (4~10) and NaCl concentra-
tions (0~1.0 M), followed by physiological pH and NaCl
conditions, after mixing overnight at room temperature
(Additional file 1: Figure S4). Both A-MNCs and HA-
MRCAs (HA-MRCA (i), HA-MRCA (ii), and HA-MRCA
(iii)) exhibited sufficient colloidal stability without aggrega-
tion under these conditions. These results assessed that A-
MNCs and HA-MRCAs are highly potent to serve as MR
contrast agents [35-39]. Though MNCs were encapsulated
with organic compounds, A-MNCs and HA-MRCAs pre-
served the crystallinities of MNCs, as demonstrated by the
characteristic X-ray diffraction (XRD) patterns at 2Θ values
of 30.3° (220), 35.8° (311), 43.6° (400), 57.5° (511), and 62.7°
(440), corresponding with the mixed spinel structure
(Figure 3a) [40]. To assess the potential of using HA-
MRCAs in MR probe applications, sensitivities to the mag-
netic field were confirmed. Regardless of phase transfer
with aminated P80 and HA conjugation, A-MNCs and
HA-MRCAs exhibited superparamagnetic properties with-
out a hysteresis loop (Figure 3b), and their saturation
magnetization values were similar and approximately 80.0
emu/gFe+Mn. Therefore, they could be used as contrast
agents of MR imaging.
Figure 2 Average size, zeta potential values, and thermo-gravimetric analysis. (a) The average size (bar graph) and zeta potential values
(gray circle) and (b) the thermo-gravimetric analysis of A-MNCs and HA-MRCAs: A-MNCs (red), HA-MRCAs (i) (blue), HA-MRCAs (ii) (green), and HA-
MCRAs (iii) (black).
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To assess the MR contrast effect of HA-MRCAs, we
performed MR imaging using HA-MRCAs, with A-
MNCs used as a control. The relaxivity coefficients were
measured and calculated (A-MNCs 361.6 mM−1 s−1,
HA-MRCAs (i) 380.0 mM−1 s−1, HA-MRCAs (ii) 366.0
mM−1 s−1, and HA-MRCAs (iii) 407.3 mM−1 s−1), and
representative T2-weighted MR images were collectedFigure 3 X-ray diffraction patterns and magnetic hysteresis loops. (a)
MRCAs with insertion of the main crystalline phases of magnetic nanocryst
MCRAs (iii) (black).(Additional file 1: Figure S5). HA-MRCAs exhibited MR
contrast effects that were remarkably higher than those
of commercial MR imaging contrast agents (ferumoxide
190.5 mM−1 s−1) based on the fact that HA-MRCAs in-
duced better contrast in MR imaging than ferumoxide
[41]. The high relaxivity coefficients of HA-MRCAs were
achieved not only by the substitution of one of the Fe
ions with a Mn ion, but also by the high crystallinity andXRD patterns and (b) magnetic hysteresis loops of A-MNCs and HA-
als: A-MNCs (red), HA-MRCAs (i) (blue), HA-MRCAs (ii) (green), and HA-
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decomposition method [42-44]. Further, relaxation rate
(R2) and the concentration of MNCs had a linear rela-
tionship in all HA-MRCAs. Therefore, the targeting effi-
ciency of HA-MRCAs could be determined based on the
concentration of the MR contrast agent in the tumor,
which should be directly proportional to the relaxivity.
Interestingly, HA-MRCAs exhibited similar or better
relaxivity compared with A-MNC. This might be attrib-
uted to the HA domain of HA-MRCAs. HA can form
many hydrogen bonds with surrounding water molecules
owing to its abundant functional groups, such as hy-
droxyl and carboxylic groups. Hydrogen bonding be-
tween HA in the coating layer of HA-MRCAs and water
molecules formed the hierarchical structures. In this
structure, the mobility of water molecules in the diffus-
ing layer is confined, and the residence time of water in-
creases due to hydrogen bonding. These phenomena
result in the enhancement of the transverse relaxation
rate [45-51]. Therefore, HA-MRCAs possessed similar
relaxivity, even after HA modification.Cell viability assay with A-MNCs and HA-MRCAs
As shown in Figure 4, the cellular toxicity values of A-
MNCs and HA-MRCAs were examined in target cancer
cells (MDA-MB-231: high CD44 expression) varied with
concentrations (2.0 × 10−2~1.25 μg/mL) for 24 h using a
cell proliferation kit. Both A-MNCs and HA-MRCAs
were found to be highly non-toxic, based on the fact
that there was greater than 80% cell viability without an
inhibitory effect on proliferation or growth in the
MDA-MB-231 cells. In particular, HA-MRCAs (ii) andFigure 4 Cell viabilities of MDA-MB-231 cells. The cells were treated wi
HA-MRCAs (i) (blue), HA-MRCAs (ii) (green), and HA-MCRAs (iii) (black).HA-MRCAs (iii) revealed lower cytotoxicity compared to
A-MNCs and HA-MRCAs (i) at high concentration (1.25
μg/mL). This is due to the positive surface charges of A-
MNCs and HA-MRCAs (i), which induced disruption and
solubilization of cell membranes by electrostatic inter-
action [52,53].Targeting efficiency of HA-MRCAs against CD44-
overexpressing cancer cells
To compare the detection efficiency of CD44 according
to the amount of HA, we investigated the targeted MR
contrast ability of HA-MRCAs against MDA-MB-231
(CD44 overexpressed) and MCF-7 (CD44 less expressed)
[22,26-28,54]. T2-weighted MR images of HA-MRCA
-treated cells were confirmed, and their MR signal inten-
sity ratio, which indicates the relaxation rate (R2) differ-
ence between HA-MRCA-treated cells and non-treated
cells (ΔR2/R2Non-treatment, where ΔR2 = R2 − R2Non-treat-
ment and R2 = T2
−1), were fitted in the MR images
(Figure 5a). Strong dark MR images and a high relaxivity
difference represented the efficient targeting ability of
HA-MRCAs. In the case of HA-MRCAs (i), a surface
charge shift from positive to neutral and insufficient
amount of HA conjugation on the A-MNCs resulted in
the weak targeting ability of HA-MRCAs (i), as shown in
MR images and signal results (1 and 0.5 μg of HA-
MRCAs (i)-treated MDA-MB 231 cells, 102.3 ± 7.6%
and 43.8 ± 0.6%; 1 and 0.5 μg of HA-MRCAs (i)-treated
MCF-7 cells, 32.7 ± 1.3% and 20.7 ± 1.9%). On the con-
trary, HA-MRCAs (ii) and HA-MRCAs (iii), which
bound more HA than HA-MRCAs (i), revealed strong
black signals in MR images of MDA-MB-231 cellsth various concentrations of A-MNCs and HA-MRCAs: A-MNCs (red),
Figure 5 MR images and graph of ΔR2/R2non-treatment. (a) T2-weighted MR images and (b) the graph of ΔR2/R2non-treatment of MDA-MB-231
(black bar) and MCF-7 (gray bar) after HA-MRCA treatment versus untreated cells at 1 and 0.5 μg of metal (Fe + Mn) concentrations.
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ing between CD44 and HA of HA-MRCAs. In addition,
these results also revealed that HA-MRCAs (ii) and
HA-MRCAs (iii) had more efficient targeting efficiency
than HA-MRCAs (i) because more HA was conjugated
(1 μg of HA-MRCAs (ii)- and HA-MRCAs (iii)-treated
MCF-7 cells, 36.9 ± 1.0% and 24.5 ± 1.7%; 0.5 μg
of HA-MRCAs (ii)- and HA-MRCAs (iii)-treated
MCF-7 cells, 26.8 ± 8.4% and 18.3 ± 1.0%; 1 μg of HA-
MRCAs (ii)- and HA-MRCAs (iii)-treated MDA-MB-231
cells, 288.4 ± 6.2% and 297.9 ± 20.5%; 0.5 μg of HA-
MRCAs (ii)- and HA-MRCAs (iii)-treated MDA-MB-231Figure 6 Relative concentrations. The relative concentrations (%) of MDA
versus untreated cells at 1 and 0.5 μg of metal (Fe + Mn) concentrations ucells, 155.3 ± 5.3% and 162.7 ± 3.0%) (Figure 5b). Using
ICP-AES, we analyzed the MNC (Fe + Mn) concentra-
tions in the cells (MDA-MB-231 and MCF-7 cells) after
treatment with HA-MRCAs, and this tended to corres-
pond with MR signal intensity (Figure 6). Consequently,
from the targeting efficacy experiments of HA-MRCAs
against CD44-abundant cancer cells, HA-MRCAs (ii) and
HA-MRCAs (iii) showed similar detection efficiencies
even though fourfold more HA was used to fabricate the
HA-MRCAs (iii). Based on these experiments, the ability
to target CD44 did not differ when the CD44 amount was
higher than the amount of HA in HA-MRCAs (ii).-MB-231 (black bar) and MCF-7 (gray bar) after HA-MRCA treatment
sing ICP-AES analysis.
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HA-MRCAs with various ratios of HA were fabricated
to determine the most efficient conditions for achieving
accurate detection of CD44-overexpressing cancer. With
HA conjugation, the surface charge changed from posi-
tive to negative, resulting in an increase in cell viability.
Then, we confirmed that HA-MRCAs exhibited similar
relaxivity in spite of the HA modification, which allowed
the comparison of targeting efficiency via MR imaging.
Varying the HA ratio could control the targeting ability
of each HA-MRCA. Especially, HA-MRCAs (ii) and
HA-MRCAs (iii) represented a sufficiently high MR im-
aging sensitivity to diagnose CD44-overexpressing can-
cer from in vitro studies. HA was modified four more
times in the fabrication of HA-MRCAs (iii) compared to
HA-MRCAs (ii); however, both HA-MRCAs (ii) and
HA-MRCAs (iii) revealed similar targeting ability. Based
on these results, HA-MRCAs (ii) appear to be appropri-
ate for diagnosis of CD44-overexpressing cancer and can
be utilized as drug carriers as well as in theragnosis sys-
tems using HA [55].
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